Publicaciones en colaboración con investigadores/as de Ankara University (19)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

2023

  1. Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis

    Psychological Assessment, Vol. 35, Núm. 2, pp. 94-114

  2. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  3. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

2022

  1. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

    Frontiers in Oncology, Vol. 12

2021

  1. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 801-812

  2. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease

    Journal of Crohn's and Colitis, Vol. 15, Núm. 6, pp. 879-913

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

  2. EAACI-Leitlinien zur allergen-spezifischen Immuntherapie: Insektengiftallergie

    Allergologie, Vol. 43, Núm. 5, pp. 176-203

  3. Survey of the impact of COVID-19 on oncologists' decision making in cancer

    JCO Global Oncology, pp. 1248-1257

2019

  1. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

    The Lancet Infectious Diseases, Vol. 19, Núm. 9, pp. 988-1000

2018

  1. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 4, pp. 744-764

  2. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 18, Núm. 10, pp. e401-e419

  3. Toxoplasmosis in transplant recipients, Europe, 2010–2014

    Emerging Infectious Diseases, Vol. 24, Núm. 8, pp. 1497-1504

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2014

  1. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

    American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362

  2. Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels

    BMC Infectious Diseases, Vol. 14, Núm. 1

2013

  1. Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial

    European Respiratory Journal, Vol. 42, Núm. 6, pp. 1622-1632

2011

  1. Bevacizumab treatment for advanced breast cancer

    Oncologist, Vol. 16, Núm. 12, pp. 1684-1697